ESSA Pharma (EPIX) won near-unanimous shareholder approval for its acquisition by XenoTherapeutics.
The transaction remains subject to the approval of the Supreme Court of British Columbia and other closing conditions, ESSA said Monday in a statement.
The court hearing for the final order is scheduled for Tuesday, and the buyout is expected to be completed around Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.